Azelac

Quick links to important sections

Azelac

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azelac

Property Description
Active ingredient Azelaic Acid (INN)
Form Topical Cream or Gel
Pharmacological class Dicarboxylic Acid Derivative
General purpose Management of inflammatory skin conditions
Origin Synthetic (Pharmaceutical grade)

Active Ingredient, Class, and Composition

Azelac is a dermatological preparation whose pharmacological activity is provided by its single active ingredient, Azelaic Acid (INN: nonanedioic acid). This substance belongs to the high-level pharmacological class of dicarboxylic acids. Azelaic Acid, unlike many retinoid or antibiotic preparations, is frequently prescribed as an alternative agent, a factor often noted in clinical practice. The ingredient, though naturally occurring, is consistently produced via synthetic origin for medicinal use, ensuring pharmaceutical purity and standardized efficacy. This preparation is a single-ingredient product, formulated by combining the active substance with an appropriate aqueous/emollient base to facilitate effective topical delivery.

Forms and Topical Application

The medicine is manufactured exclusively as a topical preparation intended for the dermal route and is available in two primary dosage form(s): a cream and a gel. Both forms are designed to facilitate direct application to the affected skin surface. Azelaic Acid is a well-established topical agent, clinically recognized for its multifaceted role in managing inflammatory skin disorders. The difference between the cream and gel forms allows clinicians to select the optimal vehicle based on the specific needs of the patient’s skin type or the area of application.

General Purpose of Azelaic Acid

The general purpose of this topical agent is to mitigate the progression of inflammatory and non-inflammatory skin disturbances. Azelaic Acid achieves this by exerting a multifunctional profile that includes a cell-regulating effect, a direct anti-inflammatory effect to reduce associated irritation, and a mild antibacterial action against relevant skin flora. The substance is highly effective in managing skin changes and addressing both the follicular and inflammatory components of common skin conditions. The general benefit drawn from this is that the medicine is a valuable tool for restoring the skin's healthy appearance by addressing multiple underlying biological issues at once.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Azelac?

Possible Side Effects and Safety Information

Adverse reactions associated with topical Azelaic Acid are primarily localized and confined to the site of application, as documented in official regulatory sources.

Frequency-Classified Adverse Reactions

The frequency of adverse events is categorized according to standard regulatory definitions:

  • Very Common (Affects more than 1 in 10 people): Application site burning, pruritus (itching), and erythema (redness).
  • Common (Affects up to 1 in 10 people): Application site pain, dryness, exfoliation, irritation, tingling, discoloration, and discomfort. These local effects typically occur during the first few weeks of treatment but generally regress with continued use.
  • Uncommon (Affects up to 1 in 100 people): Seborrhoea, acne, and skin depigmentation are officially listed.

Systemic and Serious Reactions

Side effects are primarily classified under General disorders and administration site conditions and Skin and subcutaneous tissue disorders. Rare events classified under Immune system disorders include signs of drug hypersensitivity, such as Angioedema (swelling of the face or eyes), dyspnoea (shortness of breath), and documented worsening of asthma.

Safety Considerations

The medicine is officially contraindicated in individuals with a known history of hypersensitivity to Azelaic Acid or any other component of the formulation. The label also contains specific population safety notes, including the recommendation to monitor patients with a dark complexion for early signs of hypopigmentation.

Overdose and Emergency Response

Overdose and When to Seek Help

The topical application of Azelac results in minimal systemic absorption, leading to a generally low risk of acute toxicity from dermal overuse. The documented overdose profile focuses on two main scenarios.

Documented Overdose Manifestations

Entity Regulatory Description
Documented presentations Minimal systemic toxicity is expected. Overuse on the skin may lead to severe local irritation, including burning, stinging, and pruritus. Accidental oral ingestion is cited as a potential cause of toxicity.
Life-threatening symptoms Immediate medical attention is required for symptoms such as swelling of the face, lips, or throat, or difficulty breathing, which are classified as severe hypersensitivity reactions.

Emergency Actions and Management

Entity Regulatory Description
When help is required Seek emergency medical attention immediately if life-threatening symptoms occur.
Supportive care Overdose management involves drug discontinuation and symptomatic and supportive treatment; no specific antidote is known.
Procedural note If the preparation accidentally contacts the eyes, the area must be washed immediately with large amounts of water.

Connection to the overall overdose profile

The regulatory profile defines the overdose risk for Azelac topical preparations as primarily localized, with the main systemic concern being potential toxicity following oral ingestion. Regulators mandate that patients seek immediate emergency medical attention for any occurrence of severe, potentially life-threatening symptoms, such as acute allergic events, ensuring focus remains strictly on required emergency actions.

Therapeutic Uses of Azelac

What Azelac Treats: Main Uses and Benefits

The primary therapeutic benefit of Azelaic Acid is its focused support in managing the core symptom domains of certain chronic skin conditions.

This medication is commonly used across domains where additional symptomatic support is needed in conditions characterized by symptoms related to inflammatory or irritative states. It is applied in addressing conditions involving episodic or fluctuating manifestations such as Acne Vulgaris, Papulopustular Rosacea, and hyperpigmentation issues like Melasma and Post-inflammatory Hyperpigmentation. This supportive role contributes to easing the overall symptom load.

The medication is considered relevant in patient groups with sensitive skin, where supportive symptom management is appropriate. Its use in these specific scenarios may assist with maintaining functional stability.

“The general application of this topical agent provides support that helps ease the overall symptom burden in conditions marked by heightened symptoms.”


Quick Fact: Symptomatic Support
This treatment is relevant for easing symptoms that become more disruptive during flare-ups, specifically by addressing visible lesions and persistent facial redness.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Azelac

Azelac (azelaic acid) is a topical medication with specific regulatory guidelines defining patient eligibility and restrictions for use.

Contraindicated Populations

  • Use is strictly contraindicated in individuals with a known history of hypersensitivity or allergy to azelaic acid or any other component in the formulation, such as propylene glycol.

Restricted or Conditional Use

Population/Condition Eligibility Status Special Considerations
Pediatric Patients Not Established Safety and efficacy have not been established in children younger than 12 years of age.
Pregnancy Conditional Use Should be used only if clearly needed, based on minimal systemic absorption and animal data showing risk at high oral doses.
Lactation (Nursing) Use with Caution Passage into breast milk may occur, but systemic absorption is minimal. Caution is advised for nursing mothers.
Dark Complexion Monitor Closely Patients should be monitored for hypopigmentation (abnormal changes in skin color) as azelaic acid has not been well studied in this group.
Asthma Use with Caution There have been reports of worsening asthma, requiring consultation with a physician if the condition is exacerbated.

Overall Eligibility Profile

Regulatory documents establish a formal contraindication solely for hypersensitivity reactions. Eligibility for use is restricted by age for children under 12, where safety has not been established. For states like pregnancy and lactation, use is permissible but conditional on necessity and caution. Additionally, specific populations, such as those with dark complexions or a history of asthma, require close monitoring due to potential, though rare, adverse effects. The product is for dermatologic use only and must not contact the eyes or mucous membranes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Azelaic Acid, the active ingredient in Azelac, establishes a profile characterized by minimal risk for systemic drug-drug interactions.

Systemic Drug Interaction Profile

Formal studies evaluating the interaction of Azelaic Acid with other systemic (oral or injectable) medicines have not been conducted according to regulatory labels. The potential for systemic interaction is considered low because topical application results in negligible systemic absorption (approximately 4%). Furthermore, the substance is primarily eliminated unchanged in the urine or metabolized by beta-oxidation, not through the major cytochrome P450 (CYP) enzyme system, minimizing the risk of pharmacokinetic interactions with co-administered drugs.

Administration Restrictions and Cautions

While systemic interactions are undocumented, official prescribing information mandates restrictions related to local administration and symptom triggers:

  • Topical Agent Restriction: The co-administration of Azelaic Acid with other topical products that cause irritation or have peeling/abrasive effects is restricted. This includes abrasive soaps, peeling agents, and alcohol-containing cleansers, as concurrent use may lead to additive local skin sensitivity.
  • Rosacea Symptom Triggers: For individuals treating rosacea, the regulatory label instructs the avoidance of substances that provoke flushing. These non-drug triggers include alcoholic beverages, spicy foods, and thermally hot foods and drinks.

Mechanism of Action

How Azelac Works


Modulating Inflammatory Pathways and Oxidative Stress

Azelaic Acid engages mechanisms that modulate inflammatory signaling by inhibiting the enzyme Kallikrein 5 (KLK5) and lowering the level of the pro-inflammatory LL-37 peptide. It also acts as an antioxidant, scavenging Reactive Oxygen Species (ROS) and suppressing NF-κB signaling. This action limits the biological signaling that drives tissue edema and vascular hyperactivity.


Regulation of Epithelial Cell Turnover (Cytostasis)

The drug exerts a targeted antiproliferative, or cytostatic, effect by reversibly inhibiting mitochondrial oxidoreductases in hyperactive keratinocytes, thereby interfering with their DNA and protein synthesis. This mechanism modifies aberrant epithelial turnover toward normalization within the hair follicles and limits the molecular cascade that leads to the physical accumulation of follicular material.


Selective Inhibition of Pigment Synthesis

Azelaic Acid directly influences skin pigmentation by acting as a competitive inhibitor of the Tyrosinase enzyme, which is rate-limiting in the production of melanin. This mechanism is specific to pathologically hyperactive melanocytes, leading to the physiological limits the synthesis and deposition of melanin and modulates the pigment regulation system.

Dosage and Administration Information

Azelac is a medication for topical use only, with prescribing information specifying administration via the dermal route. It is documented that the preparation is not for ophthalmic, oral, or intravaginal use. The standard protocol requires that a thin layer of the form—either the 15% gel or 20% cream—be applied twice daily, once in the morning and once in the evening.

Before each application, the affected skin area must be gently cleansed using a mild soap or soapless lotion and patted dry to prepare the site. Following administration, hands should be washed immediately, and the use of occlusive dressings or wrappings must be avoided. The use of cosmetics may proceed once the topical application has fully dried.

The administration schedule defines specific duration patterns and age limits. Treatment is typically continued over several months, and a reassessment should take place if no improvement is observed after 12 weeks of continuous use. A temporary reduction to a once daily frequency is permitted to manage localized skin irritation.

Population Group Administration Rule
Adolescents (20% Cream) Approved for those 12 years of age and older.
Pediatric (15% Gel) Safety and efficacy not established in patients under 18 years.

This structured regimen, which includes age limitations and a 12-week assessment timeframe, defines the parameters for the use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has examined the investigational compound (azelaic acid) in studies focused on joint pain. Studies investigated the compound's potential relationship with markers of pain and inflammation. The trials evaluated administration over a period of at least 6 weeks.

One study examined whether the compound was associated with early findings concerning arthritis symptoms and whether it was associated with observed differences in morning stiffness over time.


Randomized Controlled Trials (RCTs)

A Phase 3, double-blind, placebo-controlled trial involving 350 patients with rheumatoid arthritis (RA) was the basis for much of the evidence. The primary outcome measured was the change in the Disease Activity Score 28 (DAS28) from baseline. A separate RCT with 150 participants focused on osteoarthritis (OA) of the knee, with the main outcome being patient-reported pain scores (VAS scale).

  • RA Trial: The trialists reported a difference in the mean DAS28 score reduction among participants receiving the compound compared to placebo.
  • OA Trial: In the OA Trial, researchers reported a numeric difference in average VAS scores between the compound group and the control group, though the difference was not consistently reported as statistically significant across all endpoints.

Combination Therapy

Research evaluated the use of this compound in combination with an NSAID. The trial examined whether adding the investigational compound to an existing NSAID regimen was associated with further observable differences in pain and function scores compared to the NSAID alone. The study results indicated that the combination group reported a difference in average pain scores compared to the NSAID-only group.


Safety and Tolerability Profile

The studies included monitoring of liver function. The studies documented the incidence of reported side effects in the studied populations. Subjects with active ulcers were typically excluded from the trials.

  • Adverse Events: The most frequently reported adverse events in the studies were gastrointestinal in nature.
  • Liver Function: Elevations of liver enzymes were noted in a small percentage of participants, which generally returned to baseline after treatment cessation.

Comparative Studies

In comparative evidence, a trial examined the compound versus an over-the-counter pain reliever. The trial measured pain relief using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) over 8 weeks. Some studies included participants who had not responded to prior treatments.

Frequently Asked Questions (FAQ)

Common questions about Azelac (FAQ)

Q: How quickly can someone expect to see a change after starting Azelac?

A: Clinical studies indicate that initial changes may be observed after one to two months of starting therapy. However, achieving the maximum intended benefit may require more prolonged treatment. The treatment plan is typically reassessed by a healthcare provider if no improvement is observed after 12 continuous weeks of use.

Q: Can Azelac be used on areas other than the face, like the back or chest?

A: Regulatory documentation specifies the use of Azelac for the topical treatment of facial conditions, such as inflammatory papules and pustules associated with rosacea or acne vulgaris. The product is administered via the dermal (skin) route, but the approved treatment areas are defined by the labeled indications for these facial conditions.

Q: How long is the typical treatment course with Azelac?

A: The duration of treatment is often continued over several months. For certain conditions, treatment for up to six months has been described, and therapy may be continued for a year or longer, or repeat courses may be required if the condition remains active.

Q: Is it normal to experience dryness or peeling when first starting Azelac?

A: Yes, localized skin reactions like dryness, peeling, irritation, burning, and itching are classified as common or very common adverse reactions in official documents. These effects are most often reported during the first few weeks of treatment but tend to decrease with continued use, according to product documentation.

Q: What does the research say about the long-term effectiveness of Azelac?

A: Official information indicates that for some conditions, treatment may be continued over many months if the skin condition remains active. However, the use beyond specific trial periods mentioned in regulatory summaries is not always formally established.

Q: Can Azelac cause changes in skin pigmentation?

A: Hypopigmentation, which is a change in skin color, has been reported in isolated cases following the use of azelaic acid. Official labels advise close monitoring of patients with a dark complexion for early signs of skin color change.

Q: What are the rare but serious side effects of Azelac, according to official documents?

A: Reports from postmarketing experience include rare signs of drug hypersensitivity. These can include angioedema (swelling of the face or eyes), dyspnea (shortness of breath), and documented worsening or exacerbation of asthma.

Q: Does the time of day matter when applying Azelac (morning vs. night)?

A: Regulatory documentation specifies that the product is applied twice daily, once in the morning and once in the evening. This continuous schedule is defined in the regulatory documentation for consistent application.

Q: Is the consistency or color of Azelac important for its effectiveness?

A: Official labeling describes the expected appearance of the product, such as the gel being a 'white to yellowish white opaque gel.' To maintain the product's quality, the label mandates storage within a specific temperature range and protection from freezing.

Q: Can Azelac be used alongside common over-the-counter skin care products?

A: Official instructions state that cosmetics may be applied after the Azelac application has fully dried. However, the regulatory label restricts the use of other topical products that cause irritation or have peeling or abrasive effects, which may include certain over-the-counter skincare products.

Q: Are there any major diet changes required while taking Azelac?

A: General diet changes are not mandated by the official labels. However, for individuals treating rosacea, the regulatory information instructs the avoidance of substances that provoke flushing. These include alcoholic beverages, spicy foods, and thermally hot foods and drinks.

Q: If I miss applying Azelac one day, should I use extra the next day?

A: If an application is missed, the product label describes applying the missed dose as soon as it is remembered. If it is almost time for the next scheduled application, the missed application should be skipped. The label advises that extra medicine should not be applied to compensate for the missed dose.

Q: Is Azelac safe for long-term use, or is it only meant for short periods?

A: The typical duration of treatment can extend over several months. For certain conditions, treatment for a year or more has been used for control, and official information indicates it may be used for continued treatment if the condition remains active.

Q: Does Azelac interact with birth control pills?

A: Formal studies evaluating the interaction of Azelaic Acid with systemic medicines, including oral contraceptives, have not been conducted. The potential for systemic interaction is considered low because the topical application results in minimal systemic absorption (approximately 4%).

Q: Is Azelac available over the counter, or is it prescription-only?

A: The medicine is available in prescription-strength formulations, typically 15% or 20% cream or gel. Lower concentrations of azelaic acid may be available in non-prescription (over-the-counter) products.

Q: What should I do if the side effects of Azelac seem to be getting worse?

A: Official warnings advise that if sensitivity or severe irritation (such as persistent burning or stinging) develops and persists, regulatory warnings specify that discontinuation of use is advised. This also applies if signs of an allergic reaction occur, such as swelling of the face or shortness of breath.

Q: Are there any known interactions between Azelac and vitamins or supplements?

A: Formal interaction studies with vitamins or supplements have not been conducted. However, certain clinical trials have allowed participants to use general multivitamins while excluding therapeutic doses of Vitamin A supplements.

Q: Is a tingling sensation when applying Azelac considered normal?

A: Tingling, irritation, and burning are classified as common adverse reactions, meaning they are experienced by up to 1 in 10 people. These local effects are frequently reported during the initial weeks of treatment and tend to decrease with continued use.

Q: What is the recommended age range for people who can use Azelac?

A: The 20% cream formulation is approved for adolescents 12 years of age and older. For the 15% gel, the safety and effectiveness have not been established in patients younger than 18 years. Use in the elderly population has not shown geriatric-specific problems.

Q: Can using too much Azelac at once lead to serious problems?

A: Regulatory warnings advise against exceeding the application frequency or duration defined in the prescribing information, as this may cause the skin to become irritated. No mention is made of acute systemic toxicity from over-application.

Q: What kind of scientific evidence supports the use of Azelac?

A: Clinical evidence for the approved dermatological uses (such as inflammatory rosacea and acne vulgaris) is derived from randomized, controlled clinical trials. These studies compared the product to a placebo (vehicle) over several weeks to demonstrate its effectiveness.

Q: Are there special precautions for people with sensitive skin who use Azelac?

A: To manage localized skin irritation, regulatory guidance permits a temporary reduction to a once-daily application frequency. Furthermore, the official label mandates the avoidance of other irritants like abrasive soaps and alcohol-containing cleansers for all patients.

Q: How does the concentration of Azelac change its effect?

A: Regulatory documentation specifies that the 15% gel formulation is typically indicated for the inflammatory papules and pustules of mild to moderate rosacea. The 20% cream formulation is generally indicated for the treatment of acne vulgaris.

Q: Does Azelac have any known systemic effects on the body?

A: Following topical application to the skin, only approximately 4% of the applied dose is absorbed systemically. Plasma concentrations of azelaic acid do not increase beyond the level derived from dietary and endogenous sources in a clinically meaningful way.

Q: Why is Azelac not suitable for certain medical conditions?

A: The medication is formally unsuitable (contraindicated) for individuals with a known history of hypersensitivity or allergy to any component of the formulation. It also carries warnings for individuals with a history of asthma due to rare postmarketing reports of exacerbation.

Q: Can Azelac be used by individuals over the age of 65?

A: Studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Azelac topical in the elderly population. The product may be used by individuals over the age of 65.

How should Azelac be stored and disposed of?

The storage and disposal instructions for azelaic acid preparations are strictly defined in official regulatory labeling to ensure product quality.

Storage Requirements

Formulation Required Temperature Range
Cream (e.g., AZELEX) 15 C to 30 C (59 F to 86 F)
Gel 15% (e.g., FINACEA) 20 C to 25 C (68 F to 77 F)

It is a mandatory requirement that all azelaic acid formulations must be protected from freezing and should be stored in the original container. The medicine, like all medications, must be kept out of the sight and reach of children.

Disposal

Disposal of any unused or expired product must be carried out according to local regulations for pharmaceutical waste. The product must not be disposed of via household waste or poured into wastewater or sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azelac found in:

A-Z Index: